Skip to main content
. Author manuscript; available in PMC: 2010 Feb 12.
Published in final edited form as: HIV Clin Trials. 2008 Jan–Feb;9(1):11. doi: 10.1310/hct0901-11

Table 1.

Baseline Characteristics IDV+EFV
(n=143)
(Arms 1+3)
ABC+IDV+EFV
(n=140)
(Arms 2+4)
TOTAL
(n=283)
(Arms 1-4)
Gender
Men 112 (78.3) 111 (79.3) 223 (78.8)
Women 31 (21.7) 29 (20.7) 60 (21.2)
Race/Ethnicity
White, non-Hispanic 51 (35.7) 54 (38.6) 105 (37.1)
Black, non-Hispanic 60 (42) 56 (40) 116 (41)
Hispanic (any race) 30 (21) 25 (17.9) 55 (19.4)
Asian, Pac. Isl. 1 (0.7) 4 (2.9) 5 (1.8)
Amer. Ind./Alask Nat. 1 (0.7) 1 (0.7) 2 (0.7)
Age
mean 40.3 39.1 39.7
std.dev. 9.6 8.5 9.1
range 21-74 21-67 21-74
IV Drug Use
Never 119 (83.2) 108 (77.1) 227 (80.2)
Currently 1 (0.7) 2 (1.4) 3 (1.1)
Previously 23 (16.1) 30 (21.4) 53 (18.7)
Plasma HIV-1 RNAa
(log10 copies/mL)
mean 4.3 4.4 4.3
std. dev. 0.8 0.7 0.7
range 2.7 – 5.88 2.7 – 5.88 2.7 – 5.88
CD4 cell counta
(cells/mm3)
mean 125.5 141.2 133.3
std. dev. 9.6 8.5 9.1
range 0-723 0-420 0-723
a

Plasma HIV-1 RNA and CD4 values based on 142 subjects in the IDV+EFV group.

HHS Vulnerability Disclosure